Pfizer Bolstered by Acquisition of Obesity Drug Startup

about 1 month ago

Scarlett Fu

"Pfizer, of course, on the horizon, too. And some M&A news. So Pfizer ticker PFE. Those shares are soaring 2.9% at the moment. And, you know, we know that they're going to be paying $4.9 billion for this obesity drug startup, MetSera, because they do want to catch up to their rivals in that obesity drug game. So here's the kicker for the deal, though. So basically, they're agreeing to buy MetSera for $47.50 in cash per share."

Pfizer (ticker PFE) is executing a significant acquisition by buying the obesity drug startup MetSera for $47.50 per share, with additional milestone payments potentially raising the total deal value. Bloomberg Intelligence views this move favorably, suggesting it could significantly enhance Pfizer's competitive position in the obesity drug market.

Related Stocks